Digipath
Home > Boards > US OTC > Medical - Equipment >

Biotricity Inc. (BTCY)

BTCY RSS Feed
Add BTCY Price Alert      Hide Sticky   Hide Intro
Moderator: BillyBahama, Bcl40004$
Search This Board: 
Last Post: 1/19/2019 6:13:23 PM - Followers: 13 - Board type: Free - Posts Today: 0

Biotricity Inc.
http://www.biotricity.com
 

Company Overview


Biotricity is a medical technology company committed to improving healthcare by developing solutions that aid in chronic disease prevention and management. We specialize in remote monitoring solutions for chronic illnesses and adjacent connected healthcare applications in the diagnostic and post-diagnostic markets, for both medical and consumer use markets.

Our R&D focus is the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. Our proprietary remote patient monitoring platform can be leveraged for various industries and plans are underway to pipeline new solutions across a spectrum of health applications, including remote COPD monitoring, fetal monitoring, sleep apnea monitoring, and other chronic conditions.

With soaring rates of chronic disease overwhelming the healthcare system, the opportunity is ripe for technology that enables physicians to diagnose and monitor patients with chronic conditions. With physicians’ input and our deep knowledge of the industry, we set about creating solutions that bridge the gap in the marketplace between the healthcare system and the people it treats. That’s why we founded Biotricity and continue to focus on R&D to bring technologically advanced solutions to market in order to help physicians diagnose and monitor patients—and help patients make successful lifestyle changes after initial diagnosis.

Our premier product, Bioflux, is a single, integrated mobile cardiac telemetry solution that consists of a proprietary mobile ECG monitoring device and an ECG viewer software package. Bioflux enables physicians to remotely monitor and diagnose patients with cardiovascular coronary heart disease by detecting and transmitting probable arrhythmias, along with other diagnostic heart information. Together with our proprietary software, highly customizable reports, and 24/7 monitoring center, the Bioflux system is a complete solution for remote cardiac monitoring that can be integrated seamlessly into physicians’ existing workflows.

 

 

Board of Directors
 

Waqaas Al-Siddiq

Chairman, CEO & Founder

Waqaas, the founder of Biotricity, is a serial entrepreneur, a former investment advisor and an expert in wireless communication technology. Academically, he was distinguished for his various innovative designs in digital, analog, embedded, and micro-electro-mechanical products. His work was published in various conferences such as IEEE and the National Communication Council.

Waqaas has held several high-level design positions in IBM, AMD, and Intel. His achievements have been numerous in both the technical and academic world. Coupled with this, Waqaas has vast experience in leading various groups through his board experience and executive roles within start-ups, mid-sized companies, and non-profits.

Waqaas has a dual Bachelor’s degree in Computer Engineering and Economics, a Master’s in Computer Engineering from Rochester Institute of Technology, and a Master’s in Business Administration from Henley Business School. He is completing his Doctorate in Business Administration at Henley, with a focus on Transformative Innovations and Billion Dollar Markets.

 

Norman Betts, Phd

Independent Board Member

Norman sits on the Boards of Directors of the Bank of Canada, Tembec Inc., New Brunswick Power Corporation, 49 North Resources Inc., Adex Mining Inc., Tanzanian Royalty Exploration Inc. and the University of New Brunswick Pension Plan for Academic Employees.

Norman is an Associate Professor in the Faculty of Business Administration at the University of New Brunswick in Fredericton. He is accomplished in the field of accounting and finance, with a mix of academic, public, and private-sector experience. He is an expert in accounting regulations, and has extensive experience in audits, risk management, governance and oversight. He was a member of the New Brunswick Legislative Assembly from 1993 to 2003 and held three different cabinet posts, including Minister of Finance from 1999 to 2001. Prior to entering politics, Norman was Assistant Dean of the MBA Programme and an Associate Professor at the University of New Brunswick as well as a partner in the accounting firm Shannon, Betts & Buffett.

Norman received a PhD in Management with a concentration in accounting and finance from Queen’s University School of Business in 1992 and a Bachelor of Business Administration from the University of New Brunswick in 1978. He also holds a Fellow Chartered Accountant designation.

 

Dave Rosa

Independent Board Member

Dave has spent the past 22 years in a variety of positions in the medical device industry. He was appointed CEO of Sunshine Heart in October of 2009 and served as President and Chief Executive Officer through November 2015. Dave took Sunshine Heart Public on NASDAQ in 2012 and raised over $120M during his tenure. The Company achieved a number of clinical, regulatory and research and development milestones under his leadership. Prior to joining Sunshine Heart, he was President and CEO of Milksmart, Inc., a privately held company developing a unique stent-like agricultural technology that increases milking efficiencies, output and quality. From 2004-2008, Dave was Vice President of Global Marketing for Cardiac Surgery and Cardiology at St. Jude Medical, Inc. While at St. Jude, he developed the strategic pan for the newly formed interventional division, directed the launch of several new products and oversaw the acquisition and integration of Velocimed, a privately held company in the cardiovascular space.

From 1999-2004, Dave held executive management positions at privately held A-Med Systems, Inc., an emerging medical technology company that developed ventricular assist devices (pVADs) for acute heart failure. His roles included Vice President of Marketing and Sales, Chief Operating Officer and Chief Executive Officer. From 1995- 1999, Dave served as Product Manager for Angioplasty Balloons and Director of Intravascular Ultrasound at SCIMED Life Systems, a privately held company that was engaged in the development, manufacture and marketing of medical devices to treat cardiovascular disease. SCIMED was acquired by Boston Scientific Corporation and now operates as a subsidiary of Boston Scientific. Dave holds an M.B.A. in Marketing Management from Duquesne University and a B.S. in Commerce and Engineering from Drexel University.

 

Management Team

 
 

Waqaas Al-Siddiq

Chairman, CEO & Founder

 

John Ayanoglou

Chief Financial Officer

John has over 25 years of accounting, finance, and operations experience, having previously served as CFO of several public companies and a regulated financial institution. As CFO of Equitable Group, Mr. Ayanoglou raised over $130 million of regulatory capital in common, preferred, and debenture offerings over successive transactions, all during a period of extreme capital market turbulence, helping to successfully grow assets under administration from $6.1 billion to over $10 billion to facilitate Equitable Bank in becoming Canada’s ninth largest bank. He was also the CFO and Corporate Secretary of Xceed Mortgage Corporation, where he partnered with an entrepreneurial top team to grow the business through the successful implementation of warehouse financing lines and other securitization programs including public term securitizations of over $700 million.

John has extensive experience as a trusted business advisor working with management teams and boards on business acquisition and consolidation, risk mitigation and turnaround, to establish efficient, effective operations. He is a CA, CPA with a Bachelor of Commerce degree in Finance and Economics from the University of Toronto and his ICD.D designation from the Institute of Corporate Directors and the Rotman School of Business.

 

Amir Ali

Chief Development Officer

Amir is a serial entrepreneur with over 20 years of experience in launching companies and producing innovative products, services, and solutions. Amir is sought after for his expertise in transforming R&D technologies into products based on market needs, commercializing products for volume production, and establishing global distribution channels across the world.

Prior to joining Biotricity, Amir served as CEO at AT Labs Inc., where his team pioneered the concept of wireless mobile thin clients to access secure enterprise applications through the cloud. The efficacy of the robust solutions resulted in customers from healthcare, government, enterprise, and retail sectors, most of which spanned thousands of locations across the United States. His experience in developing such novel technologies has put him at the forefront of companies that have grown in revenue from zero to over $160 million. In his own ventures, he has worked with many leading industrial and financial institutional funders including Jafo, Bay Partners, and JP Morgan with whom he has raised over $35 million.

 

Spencer LaDow

Vice President, Engineering

Spencer is an expert in wireless communication and has worked with the United States Department of Defense. His academic career was highlighted by various innovative projects and designs. Spencer obtained his undergraduate degree while balancing a full-time job at Flightline Systems Ultra Electronics, a small defense contractor. His specialties are in the design and implementation of radio frequency, digital, analog, embedded software and PC software. Spencer also has experience in working with marketing, sales, and manufacturing teams in order to develop products for large-scale output. Spencer has a Bachelor’s degree in Computer Engineering from Rochester Institute of Technology.

 

Casey Shattuck

Global Vice President, Sales

Casey Shattuck has a strong 33-year track record for achieving growth in businesses he has managed.  He has extensive experience in leading cardiac and vascular “start-up” companies which have led to numerous successful acquisitions.  Casey has held a variety of senior management positions with Pfizer Schneider/Boston Scientific, CTS/Guidant, IVT/Boston Scientific, A-Med Systems, Lumend/J&J, Foxhollow Technologies/Covidien, Avinger, and Atheromed/Philips.  As President of iHeart Vascular, he raised the required funding to establish iHeart physician-owned partnerships in ambulatory surgery centers throughout Texas.

Casey was recruited to develop the southern US market at a start up company, Cardio Thoracic Systems.  He trained Cardiac Surgeons globally on this revolutionary technology and procedure and established Cardio Thoracic Systems as the dominant player in the southern US market which played a pivotal role in Guidant’s decision to acquire Cardio Thoracic Systems.

Casey led the sales development for three start-ups founded by Entrepreneur/Cardiologist Dr. John Simpson.  At Foxhollow Technologies, Casey was responsible for 10 Regional Directors and 70 Sales Professionals with over $40 million in revenue.  Casey served in the United States Marine Corps both as an active and reservist Marine.  He has been married to his wife for 31 years and has three children, one of whom is currently serving as a US Marine.

 

Mark Sather

Director,  Diagnostic Cardiology Solutions

Mark is a clinical and product expert in the field of diagnostic cardiology monitoring. He has over 15 years of experience in sales, product development, and clinical operations roles in both noninvasive and implantable device based cardiology companies. He is responsible for all clinical development, training, and field implementation programs for the Bioflux Mobile Cardiac Telemetry platform and will serve as the cardiology representative for the chronic disease management service line.

Prior to joining Biotricity, Mark served as the Diagnostic Cardiology Division Manager at ScottCare Cardiovascular Solutions, a wholly owned subsidiary of Berkshire Hathaway. During his nine-year tenure at ScottCare, he helped develop and launch their diagnostic cardiology and monitoring division and helped to grow it into a $10 million business. He was previously one of the principals and founders of Cardiostaff, an independent diagnostic testing facility in Austin, Texas specializing in Holter, Cardiac Event, and Mobile Cardiac Telemetry Monitoring. Mark received additional clinical and technical training during his time in the CRM division of St. Jude Medical and as the Western United States Regional Manager for Rozinn Electronics. He has also consulted for the Tulane Medical School Department of Infectious Diseases and become an industry expert in hospital based and remote patient monitoring.

Mark earned his Bachelor’s Degree in Pre-Medical Studies from Texas Lutheran University and a M.Ed. from Southwest Texas State University.

 

Advisory Board

 
 

Thomas C. Nelson

Nelson serves as the president of Share Our Strength, a national nonprofit that is ending childhood hunger in America. Prior to joining Share Our Strength in 2011, Nelson was chief operating officer for AARP, where he led the build-out of its state strategy in all 53 US states and territories. In addition to serving as an adjunct professor at Georgetown University’s McDonough School of Business, Nelson has a long history of service to civic organizations, including his current position on the board of directors of ProInspire. Other board positions include, the board of counselors for the Davis Gerontology School at the University of Southern California; the board of the Certified Financial Planner Board of Standards; and the board of Community Wealth Partners. Nelson holds a Ph.D. from the University of Southern California and an M.A. from Columbia University.

 

John Rother, JD

Mr. Rother is President and CEO of the National Coalition on Health Care, America’s oldest and most diverse group working to achieve comprehensive health system change. Prior to joining the Coalition in 2011, Rother worked at AARP for over 27 years as the Executive Vice President for Policy, Strategy, and International Affairs where he led the development of AARP’s policy positions and advocacy strategies. Under his leadership, AARP engaged in public policy research and analysis, public education, and advocacy on health and retirement issues at the federal, state and international levels. Rother wrote numerous articles and was a frequent speaker on health, retirement security, the federal budget, and the boomer generation.

Prior to that, Rother was Staff Director and Chief Counsel for the U.S. Senate Special Committee on Aging under the direction of Chairman John Heinz and served as Special Counsel for Labor and Health to U.S. Senator Jacob Javits. He has consistently been named as one of the most powerful people in Healthcare and in 2010 received the Robert Ball Award for Outstanding Achievements in Social Insurance from the National Academy of Social Insurance for “lifetime advocacy to strengthen Social Security and Medicare.”

 

Daniel Sands, MD, MPH

Dr. Sands is passionate about healthcare transformation, non-visit based care, collaboration in healthcare, and participatory medicine. He spent six years at Cisco, as chief medical informatics officer, where he provided both internal and external health IT leadership and helped key customers with business and clinical transformation using IT. Sands’ prior position was chief medical officer for Zix Corporation, a leader in secure e-mail and e-prescribing. Sands also spent 13 years at Beth Israel Deaconess Medical Center in Boston, where he developed and implemented numerous systems to improve clinical care delivery and patient engagement.

He has earned degrees from Brown University, Ohio State University and the Harvard School of Public Health, and trained at Boston City Hospital and Boston’s Beth Israel Hospital. Sands currently holds an academic appointment at Harvard Medical School and maintains a primary care practice in which he makes extensive use of health IT. He works as a consultant for a variety of innovative companies. Sands is the recipient of numerous health IT awards, has been elected to fellowship in both the American College of Physicians and the American College of Medical Informatics, and is a founder and co-chair of the board of the Society for Participatory Medicine. In 2009, he was recognized by HealthLeaders Magazine as one of “20 People Who Make Healthcare Better.”

 

Scientific & Medical Advisory Board

 
 

Reed Ferber, Ph.D., ATC

Dr. Ferber is an Associate Professor in the Faculty of Kinesiology and the Director and Chief Scientific Officer of the Running Injury Clinic at the University of Calgary. An award-winning teacher, he currently holds NSERC Discovery and Idea-2-Innovation grants and an NSERC Accelerator Award, which is given to only 125 scientists each year who are “highly original and innovative with ground-breaking advances in their area.”  Dr. Ferber has worked with world-leading wearable technology companies such as Garmin, Fitbit, and Orpyx and has extensively published research to validate and develop novel algorithms related to injury prediction and prevention. He holds a Ph.D. in sports medicine and gait biomechanics from the University of Oregon and is a board certified athletic trainer.

 

Rony Shimony, MD, FACC

Dr. Shimony is an Associate Professor of Medicine and Cardiology at the Icahn School of Medicine at Mount Sinai in New York, and is the director of Clinical Cardiology at Mount Sinai West (MSW). MSW is part of the internationally renowned Mount Sinai Health System, which encompasses a full range of cardiovascular services, including cardiovascular prevention, complex cardiac interventions, full electrophysiology services, device implantation and complex ablations, heart failure and heart transplant program with a comprehensive cardiothoracic surgical program. Shimony and his team specialize in the treatment of complex cardiovascular cases, integrating all aspects of cardiovascular medicine, coronary CT Angiography, cardiac risk reduction, electrophysiology and device (ICD/Pacemaker) management, with approximately 1,000 device visits per year.

Dr. Shimony received his BS degree in Biology, graduating Summa Cum Laude and Phi Beta Kappa from The University of New York at Albany and received his MD from The University of New York at Buffalo School of Medicine and Biomedical Sciences in 1984. He previously served as the Director of Lenox Hill Heart and Vascular out-patient Center in Manhattan, as well as the Director of Mount Sinai Heart and Vascular Center Midtown.

 

Share Structure

Market Cap
37,213,272          01/11/2019
Authorized Shares
125,000,000        01/04/2019
Outstanding Shares
29,534,343          01/04/2019
Restricted
17,460,338          01/04/2019
Unrestricted
12,074,005          01/04/2019
Held at DTC       
*Not Available
Float
27,663,584         07/29/2018
Par Value
0.00
OTCQB Member Since 11/2015
 
 
Contact Details

275 Shoreline Drive, Suite 150
Redwood City CA 94065
+1 . 650 . 832 . 1626

75 International Blvd, Suite 300
Toronto ON M9W 6L9
+1 . 416 . 214 . 4216
 

Biotricity Investor Relations

1.800.951.3348
 
Digipath
BTCY
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BTCY News: Current Report Filing (8-k) 01/17/2019 02:56:48 PM
BTCY News: Current Report Filing (8-k) 01/15/2019 02:46:07 PM
BTCY News: Quarterly Report (10-q) 11/14/2018 03:56:25 PM
BTCY News: Current Report Filing (8-k) 11/08/2018 05:11:02 PM
BTCY News: Current Report Filing (8-k) 11/05/2018 05:07:58 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#132   Twitter page for BIOTRICITY INC. $BTCY BillyBahama 01/19/19 06:13:22 PM
#131   Volume very weak today.. 83K BillyBahama 01/17/19 03:16:28 PM
#130   Bioflux marketed properly will be a major source BillyBahama 01/16/19 06:07:24 PM
#129   $400,000 in principal non- convertible notes with an BillyBahama 01/15/19 03:08:14 PM
#128   $BTCY 8-K out. BillyBahama 01/15/19 03:06:07 PM
#127   Strong close $1.615 +0.355 (28.17%) BillyBahama 01/14/19 04:02:49 PM
#126   Quarterly Report due on or before Feb 15th. $BTCY BillyBahama 01/14/19 03:45:14 PM
#125   Now that Biotricity has FDA 510(k) clearance for BillyBahama 01/14/19 02:23:43 PM
#124   Good action today. Low float, this will take BillyBahama 01/14/19 01:32:23 PM
#123   $BTCY $1.49 +0.23 (18.25%) Strong move up.. BillyBahama 01/14/19 10:54:07 AM
#122   Thanks.. 2019 will be a good year for BillyBahama 01/14/19 06:31:49 AM
#121   Billybahama. Glad to have you here . Bcl40004$ 01/13/19 06:33:12 PM
#120   Bioflux is a high-precision, single-unit mobile cardiac telemetry BillyBahama 01/13/19 08:50:05 AM
#119   Glad to see you see many issues with Bcl40004$ 01/12/19 02:46:13 PM
#118   Think of it this way , the holter Bcl40004$ 01/12/19 02:35:47 PM
#117   Click link , then click on all 2018 Bcl40004$ 01/12/19 01:49:50 PM
#116   Healthcare Wearable Device Market Exploring Future Growth 2019-2025 BillyBahama 01/12/19 09:13:23 AM
#114   The future looks bright for $BTCY BillyBahama 01/12/19 07:06:42 AM
#113   $BTCY Filings and Disclosure BillyBahama 01/12/19 06:31:13 AM
#112   $BTCY Share Structure BillyBahama 01/12/19 06:27:20 AM
#111   This is just the start of great things Bcl40004$ 01/11/19 11:53:52 PM
#110   Biotricity Inc. Home Page BillyBahama 01/11/19 05:27:20 PM
#109   The Company experienced a 211% growth in sales BillyBahama 01/11/19 05:25:25 PM
#108   Biotricity Provides End of Year Shareholder Update BillyBahama 01/11/19 05:24:36 PM
#107   News: http://www.globenewswire.com/news-release/2019/01/11/1690455/0/en/B davidsson10 01/11/19 08:04:30 AM
#106   Thanks. And good move my friend. Enki 01/10/19 01:42:44 PM
#105   People who bought in at 60 cent or Bcl40004$ 01/10/19 01:29:35 PM
#104   Why the dumping today... Enki 01/10/19 01:14:11 PM
#103   I believe it is around feb 14 or Bcl40004$ 01/08/19 01:43:59 PM
#102   What date is the 1Q report due? Can Enki 01/07/19 02:27:28 PM
#101   BTCY has made 100 thousand with just a Bcl40004$ 12/23/18 12:23:38 PM
#100   As described above, the Company has commenced the Bcl40004$ 12/22/18 12:47:25 PM
#99   As disclosed at the time of receiving the Bcl40004$ 12/22/18 12:46:41 PM
#98   CURRENT ASSETS Bcl40004$ 12/22/18 12:12:14 PM
#97   No insider selling. Heavily shorted . Look at Bcl40004$ 12/20/18 08:59:30 PM
#96   Why did this crash? Are they diluting? IvanPutski 12/19/18 03:41:19 PM
#95   Bioflux1—advanced remote cardiac monitoring technology engineered to Bcl40004$ 12/06/18 07:33:40 PM
#94   Biotricity_Vision Bcl40004$ 12/06/18 07:31:50 PM
#93   Biotricity_Technology_2 IoT Hardware Bcl40004$ 12/06/18 07:29:41 PM
#92   REDWOOD CITY, Calif., Dec. 04, 2018 (GLOBE NEWSWIRE) Bcl40004$ 12/06/18 06:25:57 PM
#91   BTCY is a medical grade biotelemetry device with Bcl40004$ 12/06/18 03:10:44 PM
#90   The Company is continuing to develop “Biopatch,” an Bcl40004$ 12/06/18 03:04:50 PM
#89   Bioflux 1.0 sales growth and market expansion achieved Bcl40004$ 12/06/18 03:02:34 PM
#88   REDWOOD CITY, Calif., Apr. 03, 2018 (GLOBE NEWSWIRE) Bcl40004$ 12/06/18 02:55:45 PM
#87   BTcy is now going after holter monitor business Bcl40004$ 12/06/18 02:51:59 PM
#86   BTcy already has fda approved device Bcl40004$ 12/06/18 02:51:12 PM
#85   BTcy is going to take market share from beat Bcl40004$ 12/06/18 02:49:42 PM
#84   BTcy is under valued Bcl40004$ 12/06/18 02:48:04 PM
#83   Artificial intelligence gets approved Portlandtrader 11/30/18 09:06:26 AM
#82   My technical analysis says bounce coming. $BTCY jjr04001 11/09/18 02:01:49 PM
PostSubject